Matrix metalloproteinase inhibitors based arylsulfonamide

A compound of Formula II ** ** Formula wherein R'1 is selected from (C3-C7), HC (O) -, heteroaryl (5-9) membered heterocycloalkyl or (4-9) Member or (C6-C12), said aryl (C6-C12) heteroaryl, (5-9) membered heterocycloalkyl and (4-9) membered optionally substituted by one or two substituents selected from hydroxy, halo, (C1- C7), carboxy, alkoxycarbonyl (C1-C7) alkoxycarbonyl, and HC (O) -; R2 and R3 are hydrogen; X is halogen, or (C1-C7); "Aryl" refers to monocyclic or bicyclic aromatic hydrocarbon groups which may be a single aromatic ring or multiple aromatic rings which are fused or linked covalently; "Heterocycloalkyl" or "heterocycle" refers to an optionally substituted, fully saturated, partially saturated or unsaturated, nonaromatic which may be fused, pendant, or spiro heterocyclic group, and having at least one heteroatom in at least one ring containing carbon atoms wherein each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur, where the ring -CH2- may be replaced by a -C (O ) -, and sulfur heteroatoms may also be optionally oxidized to groups S (O) or S (O) 2 and wherein, in fused ring system, a ring may be an aromatic heterocyclic ring, and (the) other (s) ring (s) may (n) be cycloalkyl, aryl, or heteroaryl; "Cycloalkyl" refers to monocyclic hydrocarbon monocyclic or saturated bicyclic groups; and "heteroaryl" refers to an aromatic ring system monocyclic or bicyclic, having from 1 to 8 heteroatoms selected from N, O or S; or a pharmaceutically acceptable salt thereof, or an optical isomer thereof; or a mixture of optical isomers.